UBS Group
EUCRU

UBS Group’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

UBS Group’s Portfolio EUCRU Stock Details EUCRU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-400
Closed -$3.94K – 11198
2022
Q4 		$3.94K Buy
+400
New +$3.99K ﹤0.01% 9426
2022
Q3 		– Sell
-199
Closed -$2K – 11427
2022
Q2 		$2K Sell
199
-600
-75% -$5.96K ﹤0.01% 9723
2022
Q1 		$8K Buy
799
+600
+302% +$5.95K ﹤0.01% 8752
2021
Q4 		$2K Sell
199
-1,209
-86% -$12.1K ﹤0.01% 9890
2021
Q3 		$14K Buy
1,408
+30
+2% +$300 ﹤0.01% 7620
2021
Q2 		$14K Sell
1,378
-1,300
-49% -$13.1K ﹤0.01% 7736
2021
Q1 		$27K Buy
2,678
+930
+53% +$9.91K ﹤0.01% 7113
2020
Q4 		$19K Buy
+1,748
New +$17.8K ﹤0.01% 7000

Other funds holding EUCRU

Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

UBS Group's EUCRU Position: Q1 2023 in Review

UBS Group sold out of Eucrates Biomedical Acquisition Corp. Unit (EUCRU) in Q1 2023, closing a stake of 400 shares — an estimated $3.94K sold.

UBS Group first reported a position in EUCRU in Q4 2020 and held it in 8 quarters. The position peaked at $27K in Q1 2021. 4 funds tracked by Wall St. Rank hold EUCRU as of Q1 2023.

  • UBS Group reported no remaining Eucrates Biomedical Acquisition Corp. Unit position as of Q1 2023 after selling out during the quarter.
  • UBS Group sold 400 Eucrates Biomedical Acquisition Corp. Unit shares in Q1 2023, an estimated $3.94K.
  • UBS Group first reported a position in Eucrates Biomedical Acquisition Corp. Unit in Q4 2020 and held it in 8 quarters.
  • UBS Group's Eucrates Biomedical Acquisition Corp. Unit position peaked at $27K in Q1 2021.
  • 4 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Unit as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.